Loading
Radiotherapy is given to half of all cancer patients but few new drugs are tested alongside it. A permanent trial platform would test drug-plus-radiation pairs systematically.
Radiosensitisers and immune-radiation combinations have strong biological rationale but almost no industry sponsorship because radiotherapy is unpatentable. The CONCORDE platform in the UK tests DNA-damage-response inhibitors with thoracic radiotherapy. Extending the model to a standing multi-tumour radiotherapy-drug platform with dose-finding modules and a shared radiotherapy quality-assurance backbone would fill a systematic gap.
Shares Too many combinations to test, Cancer Research UK, Glioma & glioblastoma.
Shares Too many combinations to test, Head and neck squamous cell carcinoma.
Shares NRG Oncology, Surgery and radiotherapy cure most, get least.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/